Kobayashi Hiroya, Omiya Ryusuke, Ruiz Marta, Huarte Eduardo, Sarobe Pablo, Lasarte Juan José, Herraiz Maite, Sangro Bruno, Prieto Jesús, Borras-Cuesta Francisco, Celis Esteban
Department of Pathology, Asahikawa Medical College, Asahikawa, Japan.
Clin Cancer Res. 2002 Oct;8(10):3219-25.
The product of the carcinoembryonic antigen (CEA) gene is an attractive candidate for T-cell-based immunotherapy because it is frequently expressed in epithelial solid carcinomas. Although many CEA peptide epitopes capable of stimulating CTLs have been identified, no MHC class II-restricted T helper epitope has yet been reported.
The amino acid sequence of CEA was examined for the presence of potential T helper epitopes, and candidate peptides were used to stimulate in vitro T-cell responses.
We describe here that using an algorithm to identify promiscuous helper T-cell epitopes, a peptide of CEA occupying residue positions 653 to 667 (CEA(653-667)), was effective in inducing in vitro T helper responses in the context of the HLA-DR4, HLA-DR7, and HLA-DR 9 alleles. Most significantly, some of the peptide-reactive helper T lymphocytes were also capable of recognizing naturally processed antigen in the form of recombinant CEA protein or cell lysates from tumors that express CEA. Interestingly, the newly identified helper T-cell epitope was found to overlap with a previously described HLA-A24-restricted CTL epitope, CEA(652-660), which could facilitate the development of a therapeutic vaccine capable of eliciting both CTL and T helper responses in patients suffering from epithelial carcinomas.
These results indicate that T helper lymphocytes are capable of recognizing CEA as a tumor antigen and that epitope CEA(653-667) could be used for immunotherapy against tumors expressing CEA.
癌胚抗原(CEA)基因产物是基于T细胞免疫治疗的一个有吸引力的候选对象,因为它在上皮性实体癌中经常表达。虽然已经鉴定出许多能够刺激细胞毒性T淋巴细胞(CTL)的CEA肽表位,但尚未有MHC II类限制性T辅助表位的报道。
检测CEA的氨基酸序列中是否存在潜在的T辅助表位,并使用候选肽刺激体外T细胞反应。
我们在此描述,通过使用一种算法来鉴定多反应性辅助性T细胞表位,一个占据653至667位残基的CEA肽(CEA(653-667)),在HLA-DR4、HLA-DR7和HLA-DR9等位基因背景下能有效诱导体外T辅助反应。最显著的是,一些肽反应性辅助性T淋巴细胞也能够识别以重组CEA蛋白或来自表达CEA的肿瘤细胞裂解物形式存在的天然加工抗原。有趣的是,新鉴定的辅助性T细胞表位被发现与先前描述的HLA-A24限制性CTL表位CEA(652-660)重叠,这有助于开发一种能够在患有上皮癌的患者中引发CTL和T辅助反应的治疗性疫苗。
这些结果表明辅助性T淋巴细胞能够将CEA识别为肿瘤抗原,并且表位CEA(653-667)可用于针对表达CEA的肿瘤的免疫治疗。